MedPath

Phase 2 Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Phase 1
Recruiting
Conditions
eoplasms, Rectal
Therapeutic area: Diseases [C] - Neoplasms [C04]
Registration Number
CTIS2023-509583-22-00
Lead Sponsor
Glaxosmithkline Research & Development Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

Is at least 18 years of age (or the local legal age of consent) at the time of signing the ICF, Has histologically confirmed Stage II to III (T3-T4, N0, or T any, N+) locally advanced rectal adenocarcinoma, Has radiologically and endoscopically evaluable disease, Has an archival FFPE tissue sample that must be available and submitted to the central reference laboratory for testing at Screening, Has an ECOG performance status of 0 or 1, Has adequate organ function, Has a tumor demonstrating the presence of either dMMR status or MSI-H phenotype

Exclusion Criteria

Has distant metastatic disease, Has received prior radiation therapy, systemic therapy, or surgery for management of rectal cancer, Has a tumor that, in the investigator's judgment, is causing symptomatic bowel obstruction or otherwise requires urgent/emergent local intervention, Has a known additional malignancy that progressed or required active treatment within the past 2 years (Exceptions include adequately treated superficial skin cancers, superficial bladder cancers, and other in situ cancers), Is immunocompromised in the opinion of the investigator, Has an active autoimmune disease that has required systemic treatment in the past 2 years, Is receiving immunosuppressive medication ; Has received systemic corticosteroids, Has received or plans to receive an organ or stem cell transplant that uses donor stem cells (allogeneic stem cell transplant).

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
Âİ Copyright 2025. All Rights Reserved by MedPath